Cloprostenol (Estrumate)

Cloprostenol sodium is a synthetic analog of prostaglandin F2α (PGF2α) that has become one of the most widely used reproductive management drugs in cattle and swine production systems worldwide. This potent luteolytic agent causes rapid regression of the corpus luteum in responsive animals, resulting in decreased progesterone production and subsequent return to estrus within predictable timeframes. The development of cloprostenol and related synthetic prostaglandins revolutionized cattle reproductive management by enabling precise manipulation of the estrous cycle without requiring lengthy feeding periods or intravaginal device insertion.

The mechanism of action of cloprostenol involves binding to prostaglandin F receptors (FP receptors) on luteal cells within the corpus luteum, initiating a cascade of events that leads to structural and functional luteolysis. This binding triggers decreased blood flow to the corpus luteum, reduced progesterone synthesis, and ultimately physical degradation of the luteal tissue over 24 to 72 hours following administration. The resulting precipitous decline in circulating progesterone removes the hormonal block on the hypothalamic-pituitary axis, allowing resumption of follicular development, estrogen production, and eventual ovulation.

Cloprostenol is available as a sterile aqueous solution for intramuscular injection, typically containing 250 micrograms of cloprostenol sodium per milliliter. The synthetic analog offers several advantages over natural PGF2α including enhanced potency (approximately 100-500 times more potent than natural prostaglandin), improved metabolic stability providing longer effective half-life, and reduced smooth muscle side effects that make administration safer and better tolerated. These pharmacological improvements enable effective luteolysis with small-volume injections that can be administered rapidly in cattle handling situations.

Regulatory approval for cloprostenol in the United States covers multiple applications in cattle including synchronization of estrus, treatment of pyometra and chronic endometritis, termination of pregnancy, and induction of parturition near term. Swine applications include synchronization of estrus in weaned sows and gilts and induction of parturition. The established withdrawal period is zero days for meat and zero hours for milk discard in cattle when used according to label directions, though some formulations may have different withdrawal requirements that should be verified for specific products.

Estrus synchronization represents the primary indication for cloprostenol use in cattle breeding programs, leveraging the drug's reliable luteolytic effect to coordinate the timing of estrus across groups of cycling cattle. When administered to cattle with functional corpora lutea (typically days 5-17 of the estrous cycle), cloprostenol induces corpus luteum regression and return to estrus within 48 to 96 hours in the majority of treated animals. This synchronization capability enables efficient breeding management through concentrated heat detection periods or fixed-time artificial insemination protocols that eliminate heat detection requirements entirely.

Treatment of pyometra and chronic post-breeding endometritis utilizes cloprostenol's luteolytic action to open the cervix and enable uterine clearance in cattle with persistent corpus luteum maintaining uterine infection. The sustained progesterone production from the corpus luteum in pyometra cases keeps the cervix closed and prevents natural drainage, perpetuating infection indefinitely. Cloprostenol administration causes luteolysis and subsequent estrus, during which the open cervix and increased uterine contractility facilitate evacuation of purulent material and recovery of normal uterine function. Treatment success rates exceed 80% for most pyometra cases when combined with appropriate supportive therapy.

Pregnancy termination represents an important application of cloprostenol for various management scenarios including mismating correction, genetic defect management, and production timing considerations. Administration at any stage of gestation typically results in fetal loss within days, though the specific timeline varies with gestational age. Early pregnancy termination following accidental exposure to undesirable bulls enables recovery of breeding potential without extended pregnancy and nursing intervals. Later gestational terminations may be indicated for genetic abnormalities detected through testing or for management reasons requiring pregnancy elimination.

Parturition induction near term uses cloprostenol's ability to initiate labor when administered within approximately two weeks of expected calving date. This application enables scheduling of calvings during periods when intensive observation is available, reducing losses from unattended dystocia. Parturition induction protocols typically combine cloprostenol with corticosteroids to optimize fetal lung maturation and reduce complications in calves delivered somewhat prematurely. The predictable calving timing following treatment enables labor planning and improved neonatal calf management.

Swine applications of cloprostenol include farrowing induction and estrus synchronization in weaned sows. Farrowing induction schedules deliveries during daylight hours when attendants are available to assist with piglet management, reducing stillbirth rates and improving piglet survival. Estrus synchronization in sows enables batch farrowing systems where groups of sows are bred and farrow together, simplifying management and enabling efficient use of boars or AI resources. The drug's effectiveness in swine reproductive management has established it as a standard tool in modern pork production systems.

The standard dosage of cloprostenol for cattle is 500 micrograms (2 mL of 250 mcg/mL solution) administered as a single intramuscular injection. This dose provides reliable luteolysis in cattle with functional corpora lutea responsive to prostaglandin treatment. Some protocols utilize 250 micrograms for synchronization applications in heifers or when maximum economy is desired, though the reduced dose may produce slightly lower synchronization rates in some populations. Higher doses have not demonstrated improved efficacy and are not recommended.

Swine dosing of cloprostenol typically ranges from 175 to 250 micrograms per animal depending on product labeling and specific application. Farrowing induction protocols commonly employ 175 micrograms administered on day 114 of gestation, producing farrowing within 24 to 36 hours in the majority of treated sows. Estrus synchronization in weaned sows may utilize similar or slightly higher doses according to manufacturer recommendations for the specific product employed.

The route of administration for cloprostenol is intramuscular injection, with the gluteal or neck muscles representing preferred injection sites in cattle. In cattle, proper restraint in a chute enables safe administration using 18-gauge needles for viscous formulations or 20-gauge for more fluid products. The injection volume (typically 2 mL for the standard cattle dose) allows rapid administration during routine processing procedures. In swine, neck or ham musculature provides suitable injection sites when animals are appropriately restrained.

Treatment timing relative to the estrous cycle significantly affects cloprostenol response in cattle. The corpus luteum becomes responsive to prostaglandin-induced luteolysis approximately 5 to 6 days after ovulation, with maximum sensitivity achieved by day 7 and maintained through day 17 of the cycle. Administration before day 5 typically fails to induce luteolysis due to luteal immaturity, while treatment after day 17 may occur too close to natural regression to provide meaningful synchronization effect. Two-injection protocols administered 11-14 days apart ensure that all cycling cattle receive at least one treatment during the responsive luteal phase.

Combination protocols integrate cloprostenol with other reproductive hormones for optimized synchronization outcomes. The CO-Synch protocol administers GnRH at the start of the protocol to synchronize follicular waves, followed by prostaglandin 7 days later to induce luteolysis, with optional GnRH at fixed-time AI to synchronize ovulation. CIDR-based protocols incorporate prostaglandin at or near device removal to ensure luteolysis in cattle that may have developed corpora lutea during progesterone treatment. Protocol selection should consider cattle population characteristics, facility capabilities, and breeding program objectives.

Withdrawal times for cloprostenol in cattle are zero days for meat and zero hours for milk discard when used according to label directions, reflecting rapid drug clearance and absence of tissue residue concerns. These favorable withdrawal times enable use in lactating dairy cattle without milk loss, though some product formulations may have different withdrawal requirements. Swine withdrawal times vary by product and should be verified against specific label requirements, though typically remain relatively short due to rapid prostaglandin metabolism.

Cloprostenol administration in cattle commonly produces transient side effects related to smooth muscle stimulation that are generally self-limiting and clinically insignificant. The most frequently observed effects include increased respiratory rate, mild sweating, and transient salivation occurring within minutes of injection and typically resolving within 15 to 30 minutes. These effects reflect the broader physiological actions of prostaglandins on smooth muscle throughout the body and do not typically require intervention or cause lasting harm.

Gastrointestinal effects including mild diarrhea and increased intestinal motility occur in some cattle following cloprostenol administration, particularly at higher doses or in sensitive individuals. These effects result from prostaglandin stimulation of intestinal smooth muscle and typically resolve within hours without specific treatment. Severe or persistent diarrhea is uncommon and should prompt veterinary evaluation to rule out concurrent disease processes.

Injection site reactions with cloprostenol are generally minimal when proper injection technique is employed, though transient swelling or mild discomfort at the injection site may occur in some animals. Reactions typically resolve within a few days without treatment. Abscesses at injection sites are rare with appropriate needle selection and aseptic technique, and any persistent swelling or drainage warrants veterinary evaluation.

Cardiovascular effects of prostaglandin administration may include transient changes in heart rate and blood pressure, though these are typically subclinical in healthy cattle. Animals with pre-existing cardiovascular compromise may be more susceptible to these effects. The synthetic analog structure of cloprostenol produces reduced cardiovascular effects compared to natural PGF2α, contributing to the improved safety profile of the synthetic compound.

Serious adverse effects from cloprostenol administration are rare in healthy cattle receiving appropriate doses. Anaphylactic reactions are theoretically possible but extremely uncommon. Deaths following prostaglandin administration have been reported in compromised animals, particularly those with severe systemic disease or cardiovascular instability. The primary safety concern with cloprostenol relates to human exposure rather than treated animal safety, emphasizing the importance of careful handling practices to protect personnel administering the drug.

Cloprostenol is contraindicated in pregnant animals when pregnancy maintenance is desired, as the drug's luteolytic action typically results in pregnancy termination regardless of gestational stage. The corpus luteum remains essential for pregnancy maintenance throughout most of gestation in cattle, and its destruction by prostaglandin administration leads to progesterone decline and subsequent abortion. Animals must be confirmed non-pregnant before cloprostenol treatment in synchronization programs where pregnancy termination would represent an adverse outcome.

Animals with respiratory disease or history of severe bronchospasm should receive cloprostenol with caution due to the bronchoconstrictive effects of prostaglandins. While severe respiratory reactions are uncommon in cattle, animals with compromised pulmonary function may experience exacerbated symptoms following prostaglandin exposure. Alternative synchronization approaches should be considered for animals with significant respiratory disease when prostaglandin treatment might pose unacceptable risk.

Cardiovascular compromise represents a relative contraindication to cloprostenol administration, as the cardiovascular effects of prostaglandins may be poorly tolerated in animals with pre-existing heart disease or circulatory instability. Cattle with severe concurrent illness, dehydration, or shock should be stabilized before elective prostaglandin treatment, and the risks and benefits of treatment in compromised animals should be carefully evaluated.

Known hypersensitivity to cloprostenol or other prostaglandin analogs contraindicates use, though documented allergic reactions to prostaglandins in cattle are extremely rare. Previous severe reactions to prostaglandin administration should prompt consideration of alternative synchronization approaches. Records of any unusual reactions should be maintained to inform future treatment decisions.

Cloprostenol interactions with GnRH products form the foundation of modern cattle synchronization protocols, representing intentional therapeutic combinations rather than adverse interactions. The sequential administration of GnRH and prostaglandin in protocols such as Ovsynch, CO-Synch, and Select Synch coordinates follicular development with luteolysis to optimize estrus synchronization and ovulation timing. These combinations have been extensively validated for safety and efficacy and represent standard reproductive management approaches.

Progesterone and progestin interactions with cloprostenol require attention to timing for optimal protocol outcomes. Administration of prostaglandin during active CIDR or MGA treatment achieves luteolysis but does not induce estrus while exogenous progestational support continues. Prostaglandin timing in progesterone-based protocols is typically coordinated with device removal or MGA withdrawal to enable the full estrous response following luteolysis. Understanding these timing relationships is essential for proper protocol implementation.

Nonsteroidal anti-inflammatory drug (NSAID) interactions with prostaglandins may theoretically reduce prostaglandin efficacy through competition at receptor sites or by inhibiting endogenous prostaglandin synthesis that contributes to the luteolytic cascade. While clinically significant interactions are uncommon at typical NSAID doses, some practitioners avoid concurrent NSAID administration during critical phases of synchronization protocols. The clinical relevance of this potential interaction remains incompletely characterized.

Corticosteroid combinations with cloprostenol are utilized in parturition induction protocols where corticosteroids (typically dexamethasone) promote fetal lung maturation while prostaglandin initiates labor. This combination produces more reliable parturition outcomes with reduced calf respiratory complications compared to prostaglandin alone when delivery occurs somewhat before full term. The timing and dosing of combination protocols should follow established veterinary recommendations for specific production scenarios.

Human safety precautions during cloprostenol handling deserve serious attention due to the significant risks posed by accidental exposure, particularly for women of childbearing potential. Prostaglandins can be absorbed through skin and mucous membranes and may induce abortion in pregnant women following inadvertent exposure. Personnel handling cloprostenol should wear impervious gloves, and pregnant women, women attempting to conceive, and individuals with asthma or other respiratory conditions should avoid any contact with the product. Accidental self-injection or skin exposure requires immediate medical attention.

Safe handling procedures for cloprostenol include wearing protective gloves during all handling operations, using appropriate needle safety practices to prevent accidental needle sticks, and immediately washing any skin contact with soap and water. Spills should be cleaned promptly using appropriate absorbent materials, and disposal should follow pharmaceutical waste requirements. Facilities should establish protocols for accidental exposure that include immediate washing and prompt medical evaluation.

Food safety considerations for cloprostenol benefit from the rapid metabolism and favorable withdrawal times established for approved uses. Compliance with label directions ensures that meat and milk from treated animals meet food safety standards without extended withdrawal periods. Operations using prostaglandins should maintain treatment records documenting animal identification, treatment dates, doses, and withdrawal period observations to support food safety compliance.

Environmental considerations for prostaglandin products include proper disposal of unused medication, empty containers, and administration equipment. Prostaglandins should not be discharged into water systems or disposed in areas accessible to animals. While prostaglandins are rapidly metabolized and environmental persistence is limited, appropriate disposal practices reflect responsible pharmaceutical stewardship.

Proper use practices to maintain cloprostenol program effectiveness include accurate pregnancy diagnosis before treatment when pregnancy termination is not intended, appropriate timing of administration relative to estrous cycle stage, and adherence to validated protocol specifications. Random prostaglandin administration without attention to cycle stage produces variable and often disappointing synchronization results. Investment in training and protocol compliance supports optimal outcomes from prostaglandin-based reproductive programs.

Storage requirements for cloprostenol injectable solutions include maintenance at controlled room temperature (typically 15-25°C or 59-77°F) protected from light and freezing. Some formulations may specify refrigerated storage, and product labeling should be consulted for specific requirements. Exposure to temperature extremes or direct sunlight may degrade the active compound, potentially reducing efficacy. Products should be visually inspected before use for particulate matter, discoloration, or other signs of degradation.

Multi-dose vial handling for cloprostenol requires aseptic technique to prevent contamination that could compromise product sterility or introduce infection risk at injection sites. Vial stoppers should be cleaned with alcohol before needle entry, and sterile needles should be used for each withdrawal. Partially used vials should be dated upon first puncture and discarded according to manufacturer recommendations or facility protocols, typically within 28 days of first use. Draw-up procedures should avoid introducing air bubbles or contamination that could affect dose accuracy or product integrity.

Disposal of cloprostenol products requires attention to both pharmaceutical disposal requirements and personnel safety considerations. Unused or expired product should be disposed through pharmaceutical waste programs rather than standard trash or sewage systems. Syringes, needles, and empty containers may contain drug residues and should be handled accordingly. Sharps containers should be used for needle disposal, and contaminated materials should be treated as pharmaceutical waste according to local regulations and facility protocols.

Species-specific considerations for cloprostenol recognize different dose requirements and applications between cattle and swine. Cattle receive the standard 500 microgram dose for most applications, while swine doses are typically lower (175-250 micrograms) reflecting species-specific sensitivity and body size differences. The drug is not approved for use in horses in the United States (though other prostaglandins are available for equine use), and use in sheep or goats would constitute extra-label application requiring veterinary guidance.

Breed sensitivities to cloprostenol have not been extensively characterized across cattle breeds, though physiological differences between Bos taurus and Bos indicus cattle may affect response to synchronization protocols. Brahman and Brahman-cross cattle demonstrate different reproductive characteristics compared to European breeds, potentially affecting optimal protocol design and expected outcomes. These breed-related differences reflect underlying reproductive physiology rather than specific drug sensitivity, but should inform protocol selection and outcome expectations.

Production type considerations differentiate cloprostenol applications between beef and dairy cattle, though the drug's approved uses encompass both production systems. Dairy operations benefit from the zero-hour milk discard that enables treatment of lactating cows without production loss, while beef operations appreciate the flexibility of incorporating prostaglandins into synchronization protocols alongside CIDR devices or GnRH products. Protocol selection and implementation may differ between production types based on handling frequency and facility design.

Age and reproductive status considerations influence expected response to cloprostenol treatment. Prepubertal heifers without functional corpora lutea will not respond to prostaglandin with estrus since no luteal tissue exists for regression. Postpartum cows in anestrus similarly lack the target tissue for prostaglandin action, though some anestrous cows may have persistent corpora lutea that respond to treatment. Proper patient selection based on reproductive status optimizes prostaglandin protocol outcomes and avoids wasted treatments in non-responsive animals.

Same-class alternatives to cloprostenol include dinoprost tromethamine (Lutalyse), which represents the natural prostaglandin F2α formulated for veterinary use. Dinoprost produces the same luteolytic endpoint through the same physiological mechanism, though the natural compound has shorter half-life and may produce more pronounced smooth muscle side effects than synthetic analogs. Selection between cloprostenol and dinoprost may reflect cost, availability, side effect profile, or practitioner preference rather than significant efficacy differences for most applications.

Other synthetic prostaglandin analogs available in various markets include fenprostalene, luprostiol, and alfaprostol, each with specific approved uses and formulation characteristics. These analogs share the fundamental mechanism of prostaglandin receptor activation and luteolysis but may differ in potency, duration of action, or side effect profiles. Availability varies by jurisdiction, and product selection should consider local regulatory approval and veterinary familiarity with specific compounds.

Different mechanism alternatives for estrus synchronization include progesterone-based approaches (CIDR devices, MGA) that control cyclicity through progestational effects rather than luteolysis. These alternatives may be used alone or in combination with prostaglandins depending on protocol design and population characteristics. GnRH products provide another complementary approach by controlling follicular wave dynamics and ovulation timing. Comprehensive synchronization programs often combine multiple mechanisms for optimal cycle control, with prostaglandins serving as the luteolytic component within multi-drug protocols.